STJ

1,216

+1.46%↑

HIK

1,461

-1.75%↓

HILS

2,755

+4.36%↑

STJ

1,216

+1.46%↑

HIK

1,461

-1.75%↓

HILS

2,755

+4.36%↑

STJ

1,216

+1.46%↑

HIK

1,461

-1.75%↓

HILS

2,755

+4.36%↑

STJ

1,216

+1.46%↑

HIK

1,461

-1.75%↓

HILS

2,755

+4.36%↑

STJ

1,216

+1.46%↑

HIK

1,461

-1.75%↓

HILS

2,755

+4.36%↑

Home・Aktien・GlaxoSmithKline PLC

GlaxoSmithKline PLC

Geschlossen

BrancheGesundheitswesen

1,913 -0.26

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1905.5

Max

1927

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.2B 1.8B
Verkäufe	-989M 7.6B
KGV Branchendurchschnitt	13.215 49.701
EPS	0.465
Dividendenrendite	3.6
Gewinnspanne	24.105
Angestellte	66,841
EBITDA	577M 2.8B

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+3.23% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	3.60% 2.39%
Nächstes Ergebnis	28. Juli 2026
Nächste Dividendenausschüttung	9. Juli 2026
Nächstes Ex-Dividendendatum	13. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.1B 75B
Vorheriger Eröffnungskurs	1913.26
Vorheriger Schlusskurs	1913

Nachrichtenstimmung

By Acuity

31%

69%

72 / 345 Ranking in Healthcare

GlaxoSmithKline PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

GlaxoSmithKline PLC Prognose

Kursziel

By TipRanks

3.23% Vorteil

12-Monats-Prognose

Durchschnitt 1,976.36 GBX 3.23%

Hoch 2,630 GBX

Tief 1,500 GBX

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für GlaxoSmithKline PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für GlaxoSmithKline PLC – Dist abgegeben haben.

Stimmung

By Acuity

72 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.